Healthcare
10x Genomics, Inc.(TXG)
Live Price
Offline$30.59
+4.83% today
1Y Change
+161.89%
Window
Jun 20, 2025 โ May 29, 2026
- Market Cap
- $2.89B
- Revenue Growth
- +5.2%
- EPS Growth
- +77.0%
- Dividend Yield
- 0.0%
Coverage: 237 bars ยท Jun 20, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
10x Genomics, Inc. (TXG) is a Healthcare stock with a market cap of $2.89B and listed on NASDAQ. The stock last traded around $30.59 and up 161.9% across the available one-year price window (Jun 20, 2025 โ May 29, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of +77.0%, a dividend yield of 0.0%. What stands out right now is revenue +5.2%, EPS +77.0%, free cash flow +2371.2% with operating margin -9.5% and ROIC -6.8%. Valuation sits in the middle of the pack at price/sales 4.5. Stock Foundry combines TXG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.2% vs +7.6% peer median
Operating Margin
Below sector median
-9.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +5.2% and EPS at +77.0%, with operating margin around -9.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +16.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -1.5% | +14.7% | โ |
2026 Feb 12, 2026 | +31.6% | +3.5% | +7.8% | +7.3% |
2025 Nov 6, 2025 | -214.3% | +17.3% | +25.8% | +36.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TXG
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TXG Max Drawdown
-28.03%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TXG and SPY.
Company Overview
10x Genomics, Inc.
NASDAQ Global Select
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
- Leadership
- Serge Saxonov
- IPO Date
- Sep 12, 2019
- Employees
- 1.3k
- Street Address
- 6230 Stoneridge Mall Road
- Mailing
- Pleasanton, CA, 94588-3260
- Region
- Pleasanton, CA, US
- Reporting Currency
- USD
- Investor Line
- 925 401 7300
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.5
- Price/Book
- 3.6
Growth
- Revenue
- +5.2%
- EPS
- +77.0%
- Free Cash Flow
- +2371.2%
Profitability
- Gross Margin
- 69.1%
- Operating Margin
- -9.5%
- Net Margin
- -6.8%
- ROE
- -5.7%
- ROIC
- -6.8%
Balance Sheet
- Debt/Equity
- 0.20
- Current Ratio
- 4.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.